Clinical trials: Emerging Infectious Diseases
COVID-19, Vaccination
Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases
Background: Vaccines against SARS-CoV-2, the virus that causes COVID-19, have been highly effective against preventing severe disease. But the protective effects of these vaccines appear to wane over time.
- Conditions
- COVID-19, Vaccination, Healthy Volunteer
- Trial name
- NCT05078905
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Post-COVID-19 Condition, Ulcerative Colitis
Emerging Indications for Hyperbaric Oxygen Treatment
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric…
- Conditions
- Post-COVID-19 Condition, Ulcerative Colitis, Crohn Disease, Calciphylaxis
- Trial name
- NCT07240649
- Testing
- Hyperbaric oxygen treatment (HBOT), 100% Oxygen
- Volunteers
- 100 people
- Sponsor
- Jay C. Buckey Jr.
Rift Valley Fever, Hemorrhagic Fevers, Viral
RVF and Other Emerging Infectious Diseases in East and Central Africa
Rift Valley fever (RVF), a disease transmitted from livestock (cattle, sheep, goats, camels) to humans more commonly occurs in the East and Central Africa (ECA) regions where more than 15 major epidemics affecting more than one…
- Trial name
- NCT05139524
- Testing
- Evidence of past or recent RVF exposure
- Where
- 10 sites in Democratic Republic of the Congo, Kenya and 2 more
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Washington State University
Ebola Virus Disease
Natural History, Disease Progression, and Long-Term Neurologic Sequelae of Ebola Virus Disease (EVD) Survivors in PREVAIL III
Background: Ebola virus disease (EVD) is a viral fever that can cause internal bleeding. The death rate from EVD is very high. In a 2014 outbreak in West Africa, 28,000 were affected and 11,000 died.
- Trial name
- NCT05494801
- Where
- Liberia
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, Telemedicine
Acceptability of Telehealth Triage Using Robotic Systems in COVID-19
The overall objective of this investigation is to understand the patient response to a robotic platform used to facilitate telehealth triage in the emergency department during the COVID-19 pandemic.
- Conditions
- COVID-19, Telemedicine, Robotics, Emergencies
- Trial name
- NCT04452695
- Testing
- Doctor Spot
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Brigham and Women's Hospital
Primary or Secondary Immune Deficiency Including Immunosuppressive Therapy, Chemotherapy, HIV Infection
Performance of Clinical Metagenomics in Stool and Urine Samples for Unexplained Diseases Diagnostic and Emerging Diseases Surveillance in Immunocompromised Patients
The study is based on the hypothesis that the concomitant use of mNGS in non-invasive samples (stool, urine) could improve the rate of detected pathogens in immunodeficient patients compared with mNGS performed in an invasive…
- Trial name
- SENTINEL (NCT07603453)
- Testing
- Metagenomics
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Invasive Candidiasis, Mucocutaneous Candidiasis
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or…
- Conditions
- Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis
- Trial name
- FURI (NCT03059992)
- Testing
- Ibrexafungerp
- Where
- 37 sites in United States, Austria and 6 more
- Volunteers
- 233 people
- Sponsor
- Scynexis, Inc.
COVID-19 Infection
Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). The global outbreak of COVID-19 is a major public health problem. COVID-19 causes a wide range of symptoms.
- Trial name
- NCT04582903
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lassa Fever
ISTH/ANRS 0409s INTEGRATE Lassa Fever Study
Lassa fever (LF) is a viral haemorrhagic fever responsible of 5000 deaths per year in West Africa, with in-hospital mortality at 12%.
- Trial name
- NCT06212336
- Testing
- Favipiravir, Ribavirin, Dexamethasone
- Where
- 4 sites in Liberia, Nigeria
- Volunteers
- 1,755 people
- Sponsor
- Irrua Specialist Teaching Hospital
Infectious Diseases, Emerging
Development of a Rapid Diagnostic Test to Identify Crimean-Congo Hemorrhagic Fever - Research and Development Testing
Background Crimean-Congo Haemorrhagic Fever (CCHF) is a rare disease with a death rate between 10% and 50%, rising to 80% during outbreaks.
- Trial name
- DETECT-R&D (NCT06894758)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Liverpool School of Tropical Medicine
Emerging Infectious Diseases, Communicable Diseases
Establishment of a Biobank for the Evaluation of Rapid Diagnostic Solutions
This multicenter prospective registry aims to establish a biobank of residual biological samples and associated clinical data from hospitalized patients.
- Conditions
- Emerging Infectious Diseases, Communicable Diseases, Biological Warfare Agents, Zoonoses
- Trial name
- NCT07411729
- Where
- 10 sites in France
- Volunteers
- 800 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Arbovirus Infections, Respiratory Infection Virus
Cohort Study of Arbovirus and Other Emerging Virus Infections in Fiji: AEVI-Fiji Cohort.
Background: Fiji, an archipelago in the South Pacific comprising 332 islands distributed among 4 health administrative divisions (Central, Western, Eastern, Northern), is particularly vulnerable to the (re-)emergence of…
- Trial name
- AEVI-Fiji (NCT07229677)
- Where
- Fiji
- Volunteers
- 910 people, healthy volunteers welcome
- Sponsor
- Fiji National University
COVID-19, Emerging Infectious Disease
EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial
EU SolidAct is a randomized, multifactorial, adaptive platform trial for COVID-19 and emerging infectious diseases and pandemics.
- Trial name
- Bari-SolidAct (NCT04891133)
- Testing
- Baricitinib
- Where
- 92 sites in Austria, Belgium and 13 more
- Volunteers
- 290 people
- Sponsor
- Oslo University Hospital
Covid19
PCR Cycle Threshold Values and COVID-19 Outcomes
This is a retrospective observational study. The study will use high quality, reliable data that has already been collected for the ISARIC 4C COVID-19 study in order to analyse the relation between predictor variables (laboratory…
- Trial name
- NCT04651413
- Testing
- PCR Value
- Where
- United Kingdom
- Volunteers
- 934 people, healthy volunteers welcome
- Sponsor
- University Hospitals of North Midlands NHS Trust
Influenza A, Influenza B
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
This randomized, open-label, multicenter phase 2 trial will assess the safety, efficacy, and pharmacokinetics (PK) of anti-influenza plasma in subjects with influenza A or B.
- Trial name
- IRC002 (NCT01052480)
- Testing
- Anti-Influenza Immune Plasma, Standard Care
- Where
- 35 sites in United States
- Volunteers
- 98 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pneumonia, Streptococcus Infection
Streptoccus Pseudopneumoniae atAssiut UniversityHospitals
Streptococcus pseudopneumoniae as suggested by DNA-DNA homology studies is recorded as a species of the Streptococcus mitis/oralis members of viridans group Streptococci; they have some similar features to the Streptococcus…
- Trial name
- NCT03528759
- Volunteers
- 100 people
- Sponsor
- Assiut University
Encephalitis, Myelitis
Neurologic Manifestations of the Arbovirus Infection in Colombia
This is a multi-center case-control study that aims to define the association between the exposure to an arbovirus infection and the development of a neurological syndrome in patients from Colombia.
- Conditions
- Encephalitis, Myelitis, Guillain-Barre Syndrome, Cranial Nerve Palsies
- Trial name
- NCT03206541
- Where
- 8 sites in Colombia
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Influenza Nos or Influenza-like Illness, Acute Respiratory Infections
A Study to Determine the Causes and Identify Increases in Influenza-Like Illness (ILI) in Mexico
The purpose of this observational study is to characterize individuals in Mexico who seek medical care for influenza-like illness (ILI) and Severe Acute Respiratory Infection (SARI), describe seasonal pattern of the pathological…
- Trial name
- NCT02378090
- Where
- 6 sites in Mexico
- Volunteers
- 888 people
- Sponsor
- Mexican Emerging Infectious Diseases Clinical Research Network
HIV Antibody Positivity
Feasibility of Positive Links for Youth Care Engagement Intervention
A small pilot study to assess feasibility and acceptability of the PL4Y intervention.
- Trial name
- NCT05689515
- Testing
- Mobile health app
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
HIV - Human Immunodeficiency Virus, HIV Antiretroviral Therapy (ART) Adherence
Improving the HIV Care Continuum With mHealth Technology
Youth living with HIV (YLHIV) face barriers to engagement and retention in HIV care, show poor medication adherence, and often fail to achieve and maintain viral suppression.
- Conditions
- HIV - Human Immunodeficiency Virus, HIV Antiretroviral Therapy (ART) Adherence, mHealth Application, mHealth Intervention
- Trial name
- NCT07631104
- Testing
- MindBodyU Intervention
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of South Carolina